What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design
文献类型：期刊论文
| 作者 | Xiong, Muya1,3; Su, Haixia1,3; Zhao, Wenfeng1; Xie, Hang1; Shao, Qiang1,3 ; Xu, Yechun1,2,3
|
| 刊名 | MEDICINAL RESEARCH REVIEWS
 |
| 出版日期 | 2021-01-18 |
| 页码 | 34 |
| 关键词 | 3C-like protease binding modes coronavirus inhibitors structure and function |
| ISSN号 | 0198-6325 |
| DOI | 10.1002/med.21783 |
| 通讯作者 | Shao, Qiang(qshao@simm.ac.cn) ; Xu, Yechun(ycxu@simm.ac.cn) |
| 英文摘要 | The emergence of a variety of coronaviruses (CoVs) in the last decades has posed huge threats to human health. Especially, the ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more than 70 million infections and over 1.6 million of deaths worldwide in the past few months. None of the efficacious antiviral agents against human CoVs have been approved yet. 3C-like protease (3CL(pro)) is an attractive target for antiviral intervention due to its essential role in processing polyproteins translated from viral RNA, and its conserved structural feature and substrate specificity among CoVs in spite of the sequence variation. This review focuses on all available crystal structures of 12 CoV 3CL(pro)s and their inhibitors, and intends to provide a comprehensive understanding of this protease from multiple aspects including its structural features, substrate specificity, inhibitor binding modes, and more importantly, to recapitulate the similarity and diversity among different CoV 3CL(pro)s and the structure-activity relationship of various types of inhibitors. Such an attempt could gain a deep insight into the inhibition mechanisms and drive future structure-based drug discovery targeting 3CL(pro)s. |
| 资助项目 | Science and Technology Commission of Shanghai Municipality[20430780300] ; National Natural Science Foundation of China[21877122] ; National Natural Science Foundation of China[32071248] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000608316400001 |
| 出版者 | WILEY |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/296114]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Shao, Qiang; Xu, Yechun |
| 作者单位 | 1.Chinese Acad Sci, CAS Key Lab Receptor Res, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharmaceut Sci & Technol, Hangzhou Inst Adv Study, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Beijing, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xiong, Muya,Su, Haixia,Zhao, Wenfeng,et al. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design[J]. MEDICINAL RESEARCH REVIEWS,2021:34. |
| APA | Xiong, Muya,Su, Haixia,Zhao, Wenfeng,Xie, Hang,Shao, Qiang,&Xu, Yechun.(2021).What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.MEDICINAL RESEARCH REVIEWS,34. |
| MLA | Xiong, Muya,et al."What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design".MEDICINAL RESEARCH REVIEWS (2021):34. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。